139 related articles for article (PubMed ID: 27329250)
1. Necitumumab in squamous non-small-cell lung cancer: how to move forward?
Garrido P; Palacios J
Ann Oncol; 2016 Aug; 27(8):1374-6. PubMed ID: 27329250
[No Abstract] [Full Text] [Related]
2. Necitumumab for the treatment of squamous cell non-small cell lung cancer.
Brinkmeyer JK; Moore DC
J Oncol Pharm Pract; 2018 Jan; 24(1):37-41. PubMed ID: 27913776
[TBL] [Abstract][Full Text] [Related]
3. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
[TBL] [Abstract][Full Text] [Related]
4. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
[TBL] [Abstract][Full Text] [Related]
5. Necitumumab: a new option for first-line treatment of squamous cell lung cancer.
Jiménez Aguilar E; Zugazagoitia Fraile J; Paz-Ares Rodríguez L
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):765-772. PubMed ID: 30025476
[TBL] [Abstract][Full Text] [Related]
6. Medical treatment of non-small-cell lung cancer.
Buter J; Giaccone G
Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463
[No Abstract] [Full Text] [Related]
7. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
[TBL] [Abstract][Full Text] [Related]
8. NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer.
Umeweni N; Knight H; McVeigh G
Lancet Oncol; 2016 Nov; 17(11):1483-1484. PubMed ID: 27692477
[No Abstract] [Full Text] [Related]
9. Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.
Takeda M; Nakagawa K
Curr Cancer Drug Targets; 2015; 15(9):792-802. PubMed ID: 26567882
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab for non-small-cell lung cancer.
Sonpavde G
N Engl J Med; 2007 Mar; 356(13):1374; author reply 1374-5. PubMed ID: 17396304
[No Abstract] [Full Text] [Related]
11. Searching for a chemoimmunotherapy signal in patients with non-small-cell lung cancer and EGFR mutations.
Pacheco JM; Camidge DR
Lancet Respir Med; 2019 May; 7(5):366-367. PubMed ID: 30922877
[No Abstract] [Full Text] [Related]
12. Cetuximab in non-small cell lung cancer.
Ademuyiwa FO; Hanna N
Expert Opin Biol Ther; 2008 Jan; 8(1):107-13. PubMed ID: 18081540
[TBL] [Abstract][Full Text] [Related]
13. Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost.
Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Ramalingam SS; Khuri FR; Flowers CR
JAMA Oncol; 2015 Dec; 1(9):1293-300. PubMed ID: 26313558
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.
Pirker R
Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis.
Young K; Paz-Ares L; Thatcher N; Spigel DR; Shahidi J; Soldatenkova V; Grau G; Kurek R; Shepherd FA
Thromb Res; 2018 Jul; 167():50-56. PubMed ID: 29787943
[TBL] [Abstract][Full Text] [Related]
16. Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer.
Joy AA; Butts CA
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S24-9. PubMed ID: 19362943
[TBL] [Abstract][Full Text] [Related]
17. [Targeted therapies. New hopes, new challenges].
Barlési F
Rev Mal Respir; 2008 Jun; 25(6):661-2. PubMed ID: 18772823
[No Abstract] [Full Text] [Related]
18. Impact of PD-L1 Expression in EGFR-Positive NSCLC? The Answer Remains the Same….
Heigener DF; Reck M
J Thorac Oncol; 2018 Aug; 13(8):1060-1061. PubMed ID: 30056859
[No Abstract] [Full Text] [Related]
19. The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
Rossi A; Bria E; Maione P; Palazzolo G; Falanga M; Gridelli C
Rev Recent Clin Trials; 2008 Sep; 3(3):217-27. PubMed ID: 18782080
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab as a single agent or in combination with chemotherapy in lung cancer.
Kim ES
Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S80-4. PubMed ID: 15638964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
